gilead infectious-diseas expertis emerg
leadership oncolog support wide moat
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research dec
estim jan
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
gilead gener stellar profit margin hiv hcv
portfolio requir small salesforc inexpens
manufactur think firm portfolio pipelin support
wide moat gilead need hcv market stabil strong
continu innov hiv solid pipelin data smart futur
acquisit return growth
gilead tenofovir tdf molecul -- viread truvada older
single-tablet regimen -- histor form heart firm
afford less like miss dose develop
drug resist need make one co-payment
newest combo pill -- replac tdf taf -- reduc bone
kidney safeti issu see rapid uptak gilead biggest
competit threat hiv glaxo triumeq saw rapid growth
glaxo launch two-drug regimen base
integras inhibitor tivicay juluca combo gener
drug lamivudin also bypass gilead drug howev
gilead genvoya odefsey descovi
biktarvi launch push patent protect late
boost gilead market share
sovaldi harvoni combin sovaldi ledipasvir
peak billion sale howev demand
shrink patient cure competit
merck led sever round signific
price-discount expect gilead eight-week
regimen mavyret share billion-plu market long term
gilead build pipelin outsid hiv hcv need
acquisit like kite car-t therapi yescarta see
strong growth gilead first cancer drug zydelig launch
limit safeti concern optimist
galapago collabor lead nash program selonsertib
also phase open multi-billion-dollar opportun
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit boost
gilead exposur cell therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
commit track record minim dec
make chang per share fair
valu estim gilead chf fair valu
estim roch follow announc
ceo roch pharmaceut divis daniel day
leav roch end becom chairman
ceo gilead effect march day
replac anderson current ceo roch
genentech roch sinc
background engin well experi
lead immunolog busi unit roch global
product strategi lower stewardship rate
gilead exemplari standard await detail
chang strategi perform previous
applaud gilead moat-build
strategi good alloc capit superior board
independ qualif
gilead year massiv manag turnov
think hire day add stabil
concern firm might still lack scientif
expertis need guid accret merger acquisit
give firm opportun fresh manag team
enter time massiv revenu headwind
hcv franchis abat feel earli
assum live prior martin/milligan team
track record see blood cancer immunolog key
area futur growth gilead fit well
day experi roch howev gilead current
relianc core hiv portfolio growth put pressur
pipelin advanc day
roch year ceo roch
pharmaceut divis sinc departur pascal soriot
window day abil make good deal
limit includ billion acquisit intermun
mildli disappoint oral ipf drug esbriet
gilead fair valu estim stand assum
billion gilead hcv sale almost
lower patient demand key headwind
follow addit price headwind
next-gener product mavyret
result see gilead hcv revenu billion
assum averag net price around
think gilead hiv/hbv franchis peak billion
 gener competit lead roughli
averag annual headwind begin
assum taf-bas combin regimen biktarvi
genvoya descovi odefsey help off-set declin
gilead could see mid-single-digit patient loss
 annual begin still view stribild
complera gener strong long-term competit
taf-bas regimen particularli outsid
gilead nash pipelin pivot data
advanc fibrosi cirrhosi patient first half
selonsertib well phase data variou
combin regimen second half
includ nash sale gilead peak north billion
annual launch begin
overal forecast averag annual sale declin
non-gaap earn declin sovaldi
lower tax rate led oper margin
shrink revenu think margin
declin assum cost-cut
help off-set margin pressur
includ billion sale yescarta
eventu surpass billion usag expand
second-lin dlbcl therapi form blood cancer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
also assum less aggress rebat
hepat market bull-cas scenario result
billion hepat sale gilead
also use slightli higher earnings-growth rate
stage ii model result fair valu
estim per share
pessimist scenario assum complera
stribild next-gener taf-bas regimen like
genvoya biktarvi unabl gain signific share
hiv market lack perceiv efficaci
safeti conveni benefit compar older
regimen glaxo doublet regimen hiv franchis sale
peak billion less uptak newer regimen
potenti price pressur gilead fall
averag annual also assum addit price
competit hepat market result less
billion hepat sale gilead
also use earnings-growth rate stage ii
model yield per share fair valu estim
patent protect newer hiv regimen gilead
continu domin hepat market
enough ensur strong return next coupl
decad gilead expertis infecti diseas
single-pil formul part research
develop strategi see one strongest
intang asset support firm wide moat
gilead moat form leadership posit
treatment hiv three patent product form
backbon today treatment regimen despit
numer competitor compani establish
lead market share spectacular profit
conveni effect safe treatment gilead serv
treat hiv patient unit state
manag done excel job maxim sale
assum cost capit gilead rate
systemat risk surround gilead share
averag assum cost equiti align
capit cost assumpt return equiti investor
like demand long run also assum
pre-tax cost debt reflect normal
gilead portfolio divers hiv focu
expand exposur hepat cancer market
still think firm warrant medium uncertainti
rate owe volatil hepat market demand
price well firm increas relianc
abil success refresh hiv busi newer
product hcv revenu declin
bullish scenario expect gilead achiev stronger
convers newer hiv product stronger
hepat price power scenario assum hiv
franchis sale peak billion follow
averag annual declin face gener competit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
tdf molecul present viread truvada
atripla complera stribild said key patent
begin expir europ next-gener product
could struggl provid suffici differenti
reimburs key market put pressur
howev think firm shown translat
extens understand drug discoveri
develop process hiv new therapeut area
allow achiev wide-moat statu despit initi
critic high price gilead paid pharmasset
earli billion acquisit gave gilead
valuabl hepat drug industri also
demonstr firm abil recogn potenti
uniqu natur sovaldi safeti efficaci profil
compar toxic nucleotid analog think
firm experi anoth nucleotid analog tenofovir
key ingredi gilead hiv combin regimen
probabl contribut recognit sovaldi valu
earli stage develop
molecul sovaldi harvoni redefin gilead
powerhous broader infecti diseas market
gilead lead way all-or treatment
hepat market gilead multi-billion-dollar
product think low resist potenti
pan-genotyp efficaci gilead regimen allow
firm retain close global hcv market
long run despit competit merck
product platform reflect grow record recogn
potenti infecti diseas discoveri
foundat hiv drug tenofovir deal brought right
emtricitabin anoth ingredi gilead
combin regimen elvitegravir integras inhibitor
stribild sovaldi gilead oncolog pipelin also
grow advanc receiv boost
recent acquisit kite includ car-t cell therapi
yescarta think firm smart acquisit
potenti futur combin regimen hematolog
oncolog immunolog nash diversifi
firm strengthen intang asset howev
think gilead hiv-rel patent exposur price
volum headwind hepat market prevent
moat expand
see grow evid firm acquisit
strategi could serv well oncolog immunolog
follow sever year smaller acquisit
idelalisib via calistoga launch safeti risk
limit usag later line therapi howev
oncolog drug safer dose zydelig combin
therapi still test sever potenti
immunolog indic well yescarta acquir
kite pharma octob launch diffus
larg b-cell lymphoma think gilead histori
smart clinic trial design market expertis could
boost launch speed long-term potenti kite
portfolio addit acquisit arresto nimbu
apollo well licens deal phenex given
gilead sever differ mechan treat nash
potenti combin key data begin read
gilead product biolog firm
vulner gener version mani older hiv
product within five year howev newer hiv regimen
seen strong launch improv kidney bone
safeti profil taf tdf support genvoya track
record fastest hiv combin pill sale ramp
record gilead latest regimen biktarvi contain
integras requir booster could pois
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
overtak gilead retain virtual econom
behind hiv sale newest combin pill rather
share partner complera johnson
 johnson atripla bristol-my squibb benefit
firm return invest capit
gilead also face strong competit hiv still see
gilead best-posit field approv
glaxo integras inhibitor tivicay combin tablet
triumeq epzicom/tivicay led gilead market share
declin glaxo gilead appear
gain share hiv player merck bristol
lack combin pill expect gilead
biktarvi glaxo juluca approv
dual-combo lamivudine/tivicay approv
continu domin market
gilead pipelin continu sale hiv beyond first
wave patent expir need counter declin
hcv tough year hcv sale
declin declin estim
roughli declin bring larger hit demand falter
launch next-gener product beyond
assum annual headwind hcv sale
remain forecast period price patient demand
declin rel steadili beyond
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ogilead market sever single-tablet regimen hiv
firm next-gener product better
long-term safeti profil led genvoya biktarvi
boost gilead market share
ogilead need rapidli convert hiv patient newer
product like genvoya biktarvi avoid
signific hit sale key patent begin
expir
oguidelin aim
improv diagnosi
treatment rate new prophylaxi use provid
strong tailwind growth hiv
owith approv sovaldi harvoni gilead
market leader all-or hepat treatment
none gilead competitor nucleotid
analog make billion acquisit
opric pressur reduc willing pay
conveni could weigh gilead growth atripla
becom formid gener competitor
gilead newer hiv product compet
hepat regimen give pbm abil
ohcv patient demand plummet visibl
long-term demand price low
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
gilead held billion cash billion debt
end gilead continu rais debt rel
low rate assum blend interest rate
includ billion debt term loan
support octob acquisit kite pharma gilead
use cash fund aggress share repurchas
billion rel new dividend gilead hiv
hcv busi also gener stellar cash flow
despit declin hcv sale gilead easili gener
around billion free cash flow annual
expect gilead use cash futur
acquisit particularli tax reform allow repatri
oversea cash note share repurchas
dial back significantli fund dividend growth
acquisit
increas competit price pressur hiv
hepat market risk gilead global price
pressur consolid pharmacy-benefit manag
could reduc gilead abil charg price premium
new drug extend patent protect gilead newest
hiv product perceiv offer significantli
improv safeti efficaci versu older hiv product
larg portion sale foundat could risk
patent gilead top market hiv product expir
firm need see signific switch
newer product like biktarvi counter neg
impact gener competitor estim
gilead -base hiv sale volum
repres govern purchas higher rebat
sale implement escal
overal healthcar cost tight budget could lead
continu elev price pressur
europ gilead also paid signific premium acquir
myogen failur darusentan put pressur
letairi make deal accret said billion
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pharmasset acquisit foundat gilead hcv
franchis allow gilead gener billion
hcv revenu alon howev gilead hcv
busi declin steepli sinc competit
allow pharmaci benefit manag like express script
aggress negoti price gilead continu
compet price split market
rel evenli gilead hiv express script could
exclud newer hiv product formulari safe
effect competit -- like gilead atripla
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
american fund invmt co amer
capit research manag compani
share
fund
share
fund
lower stewardship rate gilead
exemplari standard firm undergo manag
transit await detail chang
strategi perform previous applaud
alloc capit superior board independ
gilead year massiv manag turnov
think hire roch daniel day
new chairman ceo effect march add
stabil concern firm might still lack
scientif expertis need guid accret merger
signific turnov give firm opportun fresh
manag team enter time massiv revenu
headwind hcv franchis abat feel
earli assum live prior
immunolog key area futur growth gilead
fit well day prior experi roch
howev gilead current relianc core hiv portfolio
growth put pressur pipelin advanc
abil make strateg sound detail support
strategi day roch year
ceo roch pharmaceut divis sinc
departur pascal soriot window
day abil make accret deal limit includ
billion acquisit intermun mildli
gilead current ceo john milligan step
end along board chairman former ceo
john martin milligan spent year gilead
ceo role sinc march follow
chief scientif offic norbert bischofberg departur
end april chief medic offic andrew
cheng departur septemb milligan martin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
insid gilead board
independ lead director experienc board
member offer divers skill set includ expertis
infecti diseas global health
initi like manag reward
progress rather earn per share gilead heavi
billion share repurchas period
made valuat recent share price
current fair valu estim program shrunk
significantli sinc presum gilead save
gilead made sever acquisit collabor
deal year support infecti
diseas portfolio exampl acquisit triangl
brought emtriva critic compon truvada
firm single-tablet hiv regimen outsid
gilead therapeut area focu acquisit cv
therapeut also wise invest angina drug
ranexa grow strongli addit billion bet
pharmasset -- hepat drug sovaldi --
excel use capit earli judg
billion acquisit kite pharma current
assum deal neutral long-term roic upsid
possibl yescarta uptak faster expect kite
pipelin beyond yescarta prove lucr downsid
exist car-t therapi prove safer
treatment modal like bispecif offer similar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
commit track record minim dec
make chang per share fair
valu estim gilead chf fair valu
estim roch follow announc
ceo roch pharmaceut divis daniel day
leav roch end becom chairman
ceo gilead effect march day
replac anderson current ceo roch
genentech roch sinc
background engin well experi
lead immunolog busi unit roch global
product strategi lower stewardship rate
gilead exemplari standard await detail
chang strategi perform previous
applaud gilead moat-build
strategi good alloc capit superior board
independ qualif
gilead year massiv manag turnov
think hire day add stabil
concern firm might still lack scientif
expertis need guid accret merger acquisit
give firm opportun fresh manag team
enter time massiv revenu headwind
hcv franchis abat feel earli
assum live prior martin/milligan team
track record see blood cancer immunolog key
area futur growth gilead fit well
day experi roch howev gilead current
relianc core hiv portfolio growth put pressur
pipelin advanc day
roch year ceo roch
pharmaceut divis sinc departur pascal soriot
window day abil make good deal
limit includ billion acquisit intermun
mildli disappoint oral ipf drug esbriet
gilead perform third quarter larg line
expect product sale hcv
hiv
manag also rais revenu guidanc year
billion account weaker-than-
expect gener hiv competit europ delay
gener pah drug letairi gilead new
guidanc fit well prior billion forecast
although new forecast billion slightli
ahead guidanc given recent posit data
multipl
improv car-t
therapi yescarta upcom nash data first half
maintain per share fair valu
estim share look under-valued think investor
underestim stabil result lower
hcv sale annual expect investor could
comfort firm announc new ceo expect
later year continu think gilead establish
hiv portfolio newer drug oncolog immunolog
dive deeper nash optimist upcom
phase data selonsertib advanc fibrosi
cirrhosi patient particularli interest
combin data atla studi track
becom avail end detail
nash market analysi pleas see recent healthcar
lack credit wide-moat gilead no-moat intercept
hiv strength counter hcv weak although
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
saw encourag sign busi gilead
hiv busi perform strongli new
combin pill biktarvi drove growth hiv
revenu volum growth global hiv growth
weigh declin europ gener
launch gilead older regimen gener impact
less anticip gilead descovi see
hcv gilead saw sequenti declin sale
howev rapid declin begin annual
fourth quarter new author gener version
gilead top hcv drug harvoni epclusa launch
januari could help stabil revenu next year
product launch list price similar net price
brand version lower list price
help gilead penetr medicar part lower out-
of-pocket cost patient state-manag medicaid
see net price brand
version privat cover patient plan also
dovetail trump administr effort lower out-of-
pocket cost often base list price gilead
also look subscript model anoth innov
price strategi state might pay gilead fix
amount treat unlimit number hcv patient
given time expect stabil gilead hcv
franchis perhap slight step-down gilead
compet formulari statu mavyret see
express script decis exclud mavyret
in-pati basi
gilead top execut transit continu ceo
gilead report solid second-quart result reflect
underli strength hiv busi stabil
hepat expect make signific
chang per share fair valu estim alongsid
earn announc firm announc ceo
john milligan step end year along
current board chairman former ceo john martin
milligan spent year gilead
ceo role sinc march follow chief
scientif offic norbert bischofberg departur
end april think time logic give
firm opportun fresh manag team enter
time massiv revenu headwind hcv
franchis abat guidanc full year larg
maintain expect make signific
chang valuat model correct
slightli lower tax rate dive deeper potenti
firm nash pipelin pivot data
advanc fibrosi cirrhosi patient first half
selonsertib well phase data variou
combin regimen second half think
firm next-gener hiv therapi stabil hcv
busi potenti growth new area
oncolog cell therapi nash support wide moat
million yescarta sale show slower growth
prior quarter gilead work increas adopt
treatment center begin launch
europ yescarta approv august
addit reimburs improv octob
new add-on payment hospit although reimburs
still complic hospital-
administ therapi treatment typic given
total revenu fell second quarter
billion hiv sale grew billion
partli due slightli higher percentag sale
privat payer higher price point govern
payer also due strong launch new combin
regimen biktarvi saw million sale
first full quarter patient larg switch
older gilead regimen also glaxo triumeq tivicay
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
glaxo recent report solid data two-drug
combin lamivudin tivicay dolutegravir
treatment-nav patient think biktarvi strong
efficaci safeti profil entrench natur
three-drug regimen allow biktarvi continu
launch strongli hcv revenu fell billion
declin sequenti reflect
environ stabil price market share yescarta
sale million grow steadili launch
continu maintain estim drug
believ potenti broader blood cancer
indic potenti combin checkpoint
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
